Sivia Capital Partners LLC Takes $169,000 Position in Savara Inc (NASDAQ:SVRA)

Sivia Capital Partners LLC purchased a new stake in shares of Savara Inc (NASDAQ:SVRA) during the 4th quarter, HoldingsChannel.com reports. The fund purchased 36,000 shares of the company’s stock, valued at approximately $169,000.

Other institutional investors have also recently made changes to their positions in the company. AJOVista LLC purchased a new position in shares of Savara during the fourth quarter valued at $40,000. China Universal Asset Management Co. Ltd. purchased a new position in shares of Savara during the fourth quarter valued at $74,000. Tower Research Capital LLC TRC increased its stake in shares of Savara by 665.6% during the fourth quarter. Tower Research Capital LLC TRC now owns 19,507 shares of the company’s stock valued at $92,000 after buying an additional 16,959 shares during the period. State Board of Administration of Florida Retirement System increased its stake in shares of Savara by 19.1% during the third quarter. State Board of Administration of Florida Retirement System now owns 25,780 shares of the company’s stock valued at $97,000 after buying an additional 4,140 shares during the period. Finally, Jump Financial LLC purchased a new position in shares of Savara during the third quarter valued at $123,000. Hedge funds and other institutional investors own 87.93% of the company’s stock.

Analyst Upgrades and Downgrades

SVRA has been the topic of a number of recent research reports. JMP Securities reaffirmed a “market outperform” rating and set a $8.00 price objective on shares of Savara in a research report on Monday, May 6th. HC Wainwright reaffirmed a “buy” rating and set a $6.00 price objective on shares of Savara in a research report on Monday, May 13th. Oppenheimer raised their price objective on Savara from $9.50 to $11.00 and gave the company an “outperform” rating in a research report on Tuesday, May 21st. Piper Sandler raised their price target on Savara from $7.00 to $16.00 and gave the stock an “overweight” rating in a report on Monday, March 4th. Finally, Evercore ISI lowered their price target on Savara from $10.00 to $7.00 and set an “outperform” rating for the company in a report on Thursday, May 16th. Six analysts have rated the stock with a buy rating, According to MarketBeat.com, Savara presently has a consensus rating of “Buy” and a consensus price target of $9.17.

Savara Price Performance

Shares of NASDAQ:SVRA traded down $0.11 during trading on Monday, reaching $3.97. The stock had a trading volume of 381,579 shares, compared to its average volume of 874,150. The company has a debt-to-equity ratio of 0.22, a quick ratio of 14.90 and a current ratio of 14.90. The business has a fifty day moving average price of $4.52 and a 200-day moving average price of $4.65. The stock has a market cap of $548.61 million, a PE ratio of -11.00 and a beta of 0.70. Savara Inc has a 1-year low of $2.60 and a 1-year high of $5.70.

Savara (NASDAQ:SVRA) last issued its quarterly earnings results on Thursday, May 9th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.01). On average, equities analysts forecast that Savara Inc will post -0.41 earnings per share for the current fiscal year.

Savara Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.